Dow Tumbles Over 300 Points; Crude Oil Down 2%
U.S. stocks traded lower toward the end of trading, with the Dow Jones dipping more than 300 points on Friday.
Nasdaq Jumps Over 100 Points; Crude Oil Down 1.5%
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 100 points on Friday.
Ainos Announces Results From Additional Preclinical Study Of Its Low-Dose Oral Interferon Formulation; Showed ‘showed significant stabilization of physical condition and complete recovery from lung inflammation throughout the course of treatment period…
VELDONA® formulation showed significant stabilization of physical condition and complete recovery from lung inflammation throughout the course of treatment period.
By upregulation of immunomodulatory, Ainos'
Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday
Gainers
Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.
Why NCR Is Trading Lower By Around 23%, Here Are 42 Stocks Moving In Friday’s Mid-Day Session
Gainers
Kensington Capital Acquisition Corp. IV (NYSE: AMPX) jumped 35.4% to $13.54 after gaining 11% on Thursday.
Why Allena Pharmaceuticals Tumbled Over 30%; Here Are 85 Biggest Movers From Yesterday
Gainers
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) shares jumped 91.3% to close at $28.50 on Tuesday amid post-IPO volatility.
Recap Of Wednesday’s Biotech Catalysts – End Of the Day Summary
The European Commission (EC) has granted conditional marketing authorization (CMA) to BioMarin Pharmaceutical’s (NASDAQ:BMRN) lead asset ROCTAVIAN (valoctocogene…
Ainos Seeks FDA Nod For Mid-Stage Covid-19 Study
Ainos, Inc. (NASDAQ: AIMD) has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for conducting a Phase 2 trial of its drug candidate VELDONA, for treatment of mild symptoms related to COVID-19.
Ainos Announces Master Services Agreement With Swiss Pharmaceutical, Ltd. For Drug Testing, Manufacturing, And Packaging For Its VELDONA Product Candidates
edtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced it has signed a Master Service Agreement with